<DOC>
	<DOCNO>NCT01689155</DOCNO>
	<brief_summary>This passive-surveillance study accrue subject surveillance . For accrued subject , surveillance outcome continue six month follow first dose . If second dose give within time , surveillance continue six month follow second dose . Observational Objective : - To describe characterize adverse event occur vaccination Menactra vaccine .</brief_summary>
	<brief_title>Post-licensure Safety Surveillance Study Menactra Vaccine When Administered As 2-dose Schedule Children</brief_title>
	<detailed_description>The study carry collaboration Kaiser Permanente Medical Care Program ( KPMCP ) direction Kaiser Permanente Vaccine Study Center ( KPVSC ) . KPMCP closed-panel healthcare organization maintain comprehensive encounter databases capture medical care receive enrollee . Vaccination accord routine clinical practice . Vaccination databases review identify eligible person receive Menactra vaccine within KPMCP system .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 9 23 month time receipt first dose Menactra vaccine study period .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Infection</keyword>
	<keyword>MenactraÂ®</keyword>
</DOC>